Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2016 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects

Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growth Cosentyx...
May 17, 2016 11:30 ET | Source: NOVARTIS FINANCE S.A.

Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis

Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the...
April 21, 2016 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow...
January 27, 2016 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

Strong growth (cc) in full year sales, core operating income and core EPS[2] Net sales up 5% (cc) and core operating income up 10% (cc) Core operating income margin up 1.3 percentage points...
January 17, 2016 16:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US

Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is based...
November 04, 2015 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms....
October 27, 2015 02:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc)...
October 23, 2015 07:25 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of action...
September 25, 2015 01:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval

Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart ...
September 24, 2015 12:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E....